

JUBILANT PHARMA NV

Balance Sheet as at 31st March,	Note No	2014		2013	
		Euro	₹ '000	Euro	₹ '000
<b>I. EQUITY AND LIABILITIES</b>					
<b>Shareholders' Funds</b>					
Share capital	1	16,180,000	894,143	16,180,000	894,143
Reserves & surplus	2	1,801,442	592,563	1,809,440	356,124
		<b>17,981,442</b>	<b>1,486,706</b>	<b>17,989,440</b>	<b>1,250,267</b>
<b>Current liabilities</b>					
Trade Payables	3	17,684	1,462	9,838	683
		<b>17,684</b>	<b>1,462</b>	<b>9,838</b>	<b>683</b>
	<b>Total</b>	<b>17,999,126</b>	<b>1,488,168</b>	<b>17,999,278</b>	<b>1,250,950</b>
<b>II. ASSETS</b>					
<b>Non-current assets</b>					
Non-current investments	4	17,961,400	1,485,048	17,961,400	1,248,317
Long term loans and advances	5	22	2	13	1
		<b>17,961,422</b>	<b>1,485,050</b>	<b>17,961,413</b>	<b>1,248,318</b>
<b>Current assets</b>					
Cash & bank balances	6	37,704	3,118	37,865	2,632
		<b>37,704</b>	<b>3,118</b>	<b>37,865</b>	<b>2,632</b>
	<b>Total</b>	<b>17,999,126</b>	<b>1,488,168</b>	<b>17,999,278</b>	<b>1,250,950</b>

RAJNEESH GUPTA  
Head-Accounts

Place: Noida  
Date: 23 May, 2014

JUBILANT PHARMA NV

Statement of Profit and Loss for the year ended 31st March,	Note No	2014		2013	
		Euro	₹ '000	Euro	₹ '000
<b>REVENUE</b>					
Other income	7	33	3	64	4
<b>Total revenue</b>		<b>33</b>	<b>3</b>	<b>64</b>	<b>4</b>
<b>EXPENSES</b>					
Other expenses	8	7,992	647	7,905	553
<b>Total expenses</b>		<b>7,992</b>	<b>647</b>	<b>7,905</b>	<b>553</b>
<b>Profit before exceptional items and tax</b>		<b>(7,959)</b>	<b>(644)</b>	<b>(7,841)</b>	<b>(549)</b>
Exceptional items		39	3	(22)	(2)
<b>Profit before tax</b>		<b>(7,998)</b>	<b>(647)</b>	<b>(7,819)</b>	<b>(547)</b>
Tax expenses:					
- Current tax		-	-	-	-
		-	-	-	-
<b>Profit for the period</b>		<b>(7,998)</b>	<b>(647)</b>	<b>(7,819)</b>	<b>(547)</b>

RAJNEESH GUPTA  
Head-Accounts

Place: Noida  
Date: 23 May, 2014

JUBILANT PHARMA NV

Cash Flow Statement for the year ended 31st March,	2014		2013	
	Euro	₹ '000	Euro	₹ '000
<b>A. Cash flow arising from operating activities :</b>				
Net profit before tax	(7,998)	(647)	(7,819)	(547)
Adjustments for:				
Interest income	(33)	(3)	(64)	(4)
	(33)	(3)	(64)	(4)
Operating profit before working capital changes	(8,031)	(650)	(7,883)	(551)
Adjustments for :				
(Increase)/Decrease in trade and other receivables-current	-	-	-	-
Increase/(Decrease) in current liabilities & provisions-current	7,846	664	7,805	545
Cash generated from operations	(185)	14	(78)	(6)
Direct taxes paid (net of refunds)	(8)	(1)	25	2
Net cash inflow/(outflow) in course of operating activities	(193)	13	(53)	(4)
<b>B. Cash flow arising from investing activities :</b>				
Interest received	33	3	64	4
Movement in other bank balances	(24)	(2)	(50)	(3)
Net cash inflow/(outflow) in course of investing activities	9	1	14	1
<b>C. Foreign currency translation difference arising on conversion</b>		(7)		3
Net Increase in cash & cash equivalents (A+B+C)	(184)	7	(39)	(0)
Add: cash & cash equivalents at the beginning of year	1,766	123	1,805	123
Cash & cash equivalents at the close of the year	1,582	130	1,766	123

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

RAJNEESH GUPTA  
Head-Accounts

Place : Noida  
Date: 23 May, 2014

**JUBILANT PHARMA NV**

Notes to the Accounts as at 31st March,	2014		2013	
	Euro	₹ '000	Euro	₹ '000
<b>1. SHARE CAPITAL</b>				
<b>Authorized</b>				
17,900,000 Equity Shares of Euro 1/- each (Previous Year 17,900,000 Shares of Euro 1/- each)	17,900,000		17,900,000	
	<b>17,900,000</b>	-	<b>17,900,000</b>	-
<b>Issued &amp; Subscribed</b>				
17,900,000 Equity Shares of Euro 1/- each	17,900,000		17,900,000	
	<b>17,900,000</b>	-	<b>17,900,000</b>	-
<b>Paid up</b>				
13,900,000 Equity Shares of Euro 1/- each fully paid up	13,900,000	743,789	13,900,000	743,789
4,000,000 Equity Shares of Euro 1/- each Euro 0.57/- per share paid up	2,280,000	150,354	2,280,000	150,354
	<b>16,180,000</b>	<b>894,143</b>	<b>16,180,000</b>	<b>894,143</b>

1) The Company has only one class of shares referred to as equity shares having par value of Euro 1 each. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However, no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the company:

Particulars	As at		As at	
	31st March, 2014		31st March, 2013	
Name of the shareholder	No. of shares	% holding in the class	No. of shares	% holding in the class
Jubilant Life Sciences Limited , Holding company	13,900,000	77.65%	13,900,000	77.65%
Jubilant Pharma Pte. Ltd., Fellow subsidiary	4,000,000	22.35%	4,000,000	22.35%

4) The reconciliation of the number of shares outstanding at beginning and at end of the reporting period:

Particulars	As at	As at
	31st March, 2014	31st March, 2013
Numbers of shares at the beginning	17,900,000	17,900,000
<b>Numbers of shares at the end</b>	<b>17,900,000</b>	<b>17,900,000</b>

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

Particulars	As at	As at
	31st March, 2014	31st March, 2013
	No. of shares	No. of shares
Jubilant Life Sciences Limited , Holding company	13,900,000	13,900,000
Jubilant Pharma Pte. Ltd., Fellow subsidiary	4,000,000	4,000,000

**JUBILANT PHARMA NV**

Notes to the Accounts as at 31st March,	2014		2013	
	Euro	₹ '000	Euro	₹ '000
<b>2. RESERVES AND SURPLUS</b>				
Foreign Currency Translation Reserve				
As per last Balance Sheet		253,687		224,347
Addition/(deduction): Effect of foreign exchange rate variation during the year		237,086		29,340
		490,773		253,687
Surplus as per Statement of Profit and Loss				
As per last Balance Sheet	1,809,440	102,437	1,817,259	102,984
Add/(Less): Net Profit/(Loss) after tax as per Statement of Profit and Loss for the year	(7,998)	(647)	(7,819)	(547)
	<b>1,801,442</b>	<b>101,790</b>	<b>1,809,440</b>	<b>102,437</b>
	<b>1,801,442</b>	<b>592,563</b>	<b>1,809,440</b>	<b>356,124</b>
<b>3. TRADE PAYABLES</b>				
Others	17,684	1,462	9,838	683
	<b>17,684</b>	<b>1,462</b>	<b>9,838</b>	<b>683</b>
<b>NON-CURRENT ASSETS</b>				
<b>4. NON-CURRENT INVESTMENTS</b>				
(at cost)				
Trade Investments(Long Term)				
Investment in equity instruments(fully paid up equity shares)				
Investment in equity shares of Subsidiary Company (Unquoted)				
2,595 Equity shares of Euro 403.96/- each in Jubilant Pharmasuecticals NV (Previous Year 2595 Equity Shares)	11,891,527	983,191	11,891,527	826,461
3,980 Equity shares of Euro 166.25/- each in PSI Supply NV (Previous Year 3,980 Equity Shares)	6,069,873	501,857	6,069,873	421,856
	<b>17,961,400</b>	<b>1,485,048</b>	<b>17,961,400</b>	<b>1,248,317</b>
<b>5. LONG TERM LOANS AND ADVANCES</b>				
- Advance payment of income tax (including TDS)	22	2	13	1
	<b>22</b>	<b>2</b>	<b>13</b>	<b>1</b>
<b>CURRENT ASSETS</b>				
<b>6. Cash and bank balances</b>				
Balances with banks:				
- On current accounts	1,581	131	1,766	123
	<b>1,581</b>	<b>131</b>	<b>1,766</b>	<b>123</b>
Other bank balances:				
- Deposits with original maturity of more than 3 months and upto 12 months	36,123	2,987	36,099	2,509
	<b>37,704</b>	<b>3,118</b>	<b>37,865</b>	<b>2,632</b>

JUBILANT PHARMA NV

Notes to the Accounts for the year ended 31st March,	2014		2013	
	Euro	₹ '000	Euro	₹ '000
<b>7. OTHER INCOME</b>				
Interest Income	33	3	64	4
	<b>33</b>	<b>3</b>	<b>64</b>	<b>4</b>
<b>8. OTHER EXPENSES</b>				
Rates & taxes	1,400	111	1,999	140
Advertisement, publicity & sales promotion	-	(0)	331	23
Auditors Remuneration - As Auditors	700	57	700	49
Legal , professional & consultancy charges	5,747	467	4,790	335
Bank Charges	145	12	85	6
	<b>7,992</b>	<b>647</b>	<b>7,905</b>	<b>553</b>
<b>9. EXCEPTIONAL ITEMS</b>				
Foreign Exchange Gain/Loss	39	3	(22)	(2)
	<b>39</b>	<b>3</b>	<b>(22)</b>	<b>(2)</b>